retatrutide phase 3 2025 triple agonist glp-1 gip glucagon glp 1 lr3 Beyond GLP-1: Retatrutide's triple-agonist mechanism (GLP-1, GIP, glucagon) is redefining metabolic health. 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside Move over #retatrutide the #QuintupleAgonist

Sofwave works gradually by supporting your natural collagen production, so the results are subtle and proportionate

Studies have shown that consuming adequate amounts of folate, vitamin B6, and vitamin B12 can work synergistically to lower homocysteine levels, thus reducing the risk of heart disease (58, 59)

(2023) Phase 2 Retatrutide Trial, NEJM (PubMed) Coskun et al

Whilst mild gastrointestinal symptoms are expected and generally self-limiting during retatrutide treatment, certain presentations warrant prompt medical attention

Chronic inflammation contributes to everything from joint pain to heart disease

Long-term studies are still ongoing, so your provider weighs these risks against the benefits before prescribing